Abstract: The present invention relates to a non-human mammalian animal which has been modified to have in the blood, plasma and/or serum (a) an increased number of leukocytes and/or neutrophils, and (b) a reduced activity of the DNase 1 and/or DNase 1-like 3 enzymes. The non-human mammalian animal is particularly suitable for studying inflammation and/or a disease associated with inflammation. In a further aspect, the invention relates to the use of the non-human mammalian animal as a model for identifying therapeutic or diagnostic targets of inflammation and/or a disease associated with inflammation. In a still further aspect, the invention relates the use of the non-human mammalian animal as a model for drug candidate testing. In addition, a method for testing an anti-inflammatory drug candidate against extracellular DNA is provided. Finally, a method for testing an anti-inflammatory drug candidate for modifying the formation or degradation of neutrophil extracellular traps is provided.

Abstract: A method for enhancing at least one of craving-reduction, mood improvement, avoidance of depression, prevention of weight gain post weight-loss from dieting, reduction of negative side effects produced by anti-appetite drugs and smoke-cessation and promotion of healthy ageing in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b). The composition may comprise a third active ingredient in combination with the Cyperus esculentus extract and mangiferin or norathyriol.

Abstract: Methods and apparatuses are provided for self-trimming of a semiconductor device. An example apparatus includes a semiconductor device including a self-trimming circuit configured to receive a reference voltage and a test command signal. The self-trimming circuit is configured to convert the reference voltage to a target voltage based on the test command signal and further configured to adjust a voltage trim code until an internal voltage matches the target voltage to determine a trim level associated with the internal voltage.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: An example method may include classifying a plurality of atomic pieces of historic feedback to create an association between the plurality of atomic pieces of historic feedback and a plurality of atomic pieces of historic code associated with the plurality of atomic pieces of historic feedback; storing the plurality of atomic pieces of historic feedback and the plurality of atomic pieces of historic code to a data store; comparing the plurality of atomic pieces of historic feedback to group similar kinds of feedback; receiving a request for code review of new code; comparing the new code to the plurality of atomic pieces of historic code to measure similarities between the new code and the plurality of pieces of historic code to identify similar code from the plurality of atomic pieces of historic code; and providing feedback on the new code based on feedback associated with the similar code.

Abstract: A method for enhancing at least one of alertness, attention, concentration and memory in a person in need thereof, comprising co-administering an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; and caffeine to the person. The components may be co-administered in a single composition, or administered in separate compositions. The mangiferin and/or norathyriol exhibit synergistic effects on brain wave activity when co-administered with caffeine.

Abstract: A method for enhancing at least one of alertness, attention, concentration and memory in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b).

Abstract: The current disclosure relates to methods for treating loss of muscle mass, by administering compositions comprising a combination of: 20-hydroxy-ecdysone (20HE) or a pharmaceutically acceptable salt thereof; and at least one ecdysteroid selected from the group consisting of polypodine, makisterone A, integristerone, taxisterone, lesterone, rapisterone, inokonesterone, carthamosterone, rubrosterone, leuzeasterone, ayugasterone, turkestrone, salts thereof, and derivatives thereof. The composition optionally further comprises an effective amount of hesperidin.

Abstract: A liveness detection system comprises a controller, a video input, a feature recognition module, and a liveness detection module. The controller is configured to control an output device to provide randomized outputs to an entity over an interval of time. The video input is configured to receive a moving image of the entity captured by a camera over the interval of time. The feature recognition module is configured to process the moving image to detect at least one human feature of the entity. The liveness detection module is configured to compare with the randomized outputs a behaviour exhibited by the detected human feature over the interval of time to determine whether the behaviour is an expected reaction to the randomized outputs, thereby determining whether the entity is a living being.

Abstract: A method for enhancing at least one of craving-reduction, mood improvement, avoidance of depression, prevention of weight gain post weight-loss from dieting, reduction of negative side effects produced by anti-appetite drugs and smoke-cessation and promotion of healthy ageing in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b). The composition may comprise a third active ingredient in combination with the Cyperus esculentus extract and mangiferin or norathyriol.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: An example method may include classifying a plurality of atomic pieces of historic feedback to create an association between the plurality of atomic pieces of historic feedback and a plurality of atomic pieces of historic code associated with the plurality of atomic pieces of historic feedback; storing the plurality of atomic pieces of historic feedback and the plurality of atomic pieces of historic code to a data store; comparing the plurality of atomic pieces of historic feedback to group similar kinds of feedback; receiving a request for code review of new code; comparing the new code to the plurality of atomic pieces of historic code to measure similarities between the new code and the plurality of pieces of historic code to identify similar code from the plurality of atomic pieces of historic code; and providing feedback on the new code based on feedback associated with the similar code.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: A method for enhancing at least one of alertness, attention, concentration and memory in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b).

Abstract: The present invention provides sensor cells comprising a receptor that binds to an analyte indicative of the presence of an agent, where binding of the analyte to the receptor triggers a detection event that is indicative of the presence of the agent. In certain embodiments, the detection event is appearance of a reporter detectable by the naked eye. The present invention also provides uses of such sensor cells for detecting the presence of an agent in a sample.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as defined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: The invention relates to a bidirectional multi-level DC/DC converter and its non-linear control, adapted to transfer power between at least one energy source and an electricity distribution network.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: In accordance with an embodiment, described herein is a system and method for streaming music on mobile devices, including those which may have limited support for streaming. In response to receiving a request for portions of media content to be retrieved from a media server and played at a media device, selected parts of a media content file (e.g., an MP3 file) can be downloaded from a media server, and prepended, appended, or otherwise adjusted into a complete (albeit relatively shorter) media content, which is decoded and sent, for example to an audio speaker at the media device. The approach provides flexibility in providing access to a media streaming service from non-native mobile device applications, for example by enabling a media application to load and play encrypted MP3 file content in environments such as mobile browsers that require low memory consumption, or do not support Media Source Extensions.